Advances in the Management of Central Nervous System Metastases from Breast Cancer

被引：4

作者：

Avila, Jorge ^{[1
,2
]}

Leone, Jose Pablo ^{[3
]}

机构：

[1] St Elizabeths Med Ctr, Dept Internal Med, 736 Cambridge St, Boston, MA 02135 USA

[2] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 20期

关键词：

breast cancer; brain metastases; metastatic breast cancer; central nervous system metastases; TRASTUZUMAB EMTANSINE T-DM1; BRAIN RADIATION-THERAPY; LAPATINIB PLUS CAPECITABINE; RANDOMIZED PHASE-III; DERUXTECAN T-DXD; STEREOTACTIC RADIOSURGERY; PROGNOSTIC-FACTORS; CNS METASTASES; DOUBLE-BLIND; INTRATHECAL TRASTUZUMAB;

D O I：

10.3390/ijms232012525

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Central nervous system (CNS) metastases are common in breast cancer (BC) patients and are particularly relevant as new treatments for BC are prolonging survival. Here, we review advances in the treatment of CNS metastases from BC, including radiotherapy, systemic therapies, and the evolving role of immunotherapy. The use of radiotherapy and chemotherapy is the cornerstone of treatment for CNS metastases. However, new targeted therapies have recently been developed, including anti-HER2 agents and antibody-drug conjugates that have presented promising results for the treatment of these patients.

引用

页数：22

共 134 条

[1] Blood-brain barrier structure and function and the challenges for CNS drug delivery [J].

Abbott, N. Joan .

JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (03) :437-449

[2] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC). [J].

Anders, Carey K. ;

Le Rhun, Emilie ;

Bachelot, Thomas Denis ;

Yardley, Denise A. ;

Awada, Ahmad ;

Conte, Pier Franco ;

Kabos, Peter ;

Bear, Melissa ;

Yang, Zhengyu ;

Chen, Yanyun ;

Tolaney, Sara M. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[3] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[4] Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].

Andrews, DW ;

Scott, CB ;

Sperduto, PW ;

Flanders, AE ;

Gaspar, LE ;

Schell, MC ;

Werner-Wasik, M ;

Demas, W ;

Ryu, J ;

Bahary, JP ;

Souhami, L ;

Rotman, M ;

Mehta, MP ;

Curran, WJ .

LANCET, 2004, 363 (9422) :1665-1672

[5]

[Anonymous], Single fraction stereotactic radiosurgery compared with fractionated stereotactic radiosurgery in treating patients with resected metastatic brain disease

[6] Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial [J].

Aoyama, Hidefumi ;

Shirato, Hiroki ;

Tago, Masao ;

Nakagawa, Keiichi ;

Toyoda, Tatsuya ;

Hatano, Kazuo ;

Kenjyo, Masahiro ;

Oya, Natsuo ;

Hirota, Saeko ;

Shioura, Hiroki ;

Kunieda, Etsuo ;

Inomata, Taisuke ;

Hayakawa, Kazushige ;

Katoh, Norio ;

Kobashi, Gen .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2483-2491

[7] Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].

Awada, Ahmad ;

Colomer, Ramon ;

Inoue, Kenichi ;

Bondarenko, Igor ;

Badwe, Rajendra A. ;

Demetriou, Georgia ;

Lee, Soo-Chin ;

Mehta, Ajay O. ;

Kim, Sung-Bae ;

Bachelot, Thomas ;

Goswami, Chanchal ;

Deo, Suryanarayan ;

Bose, Ron ;

Wong, Alvin ;

Xu, Feng ;

Yao, Bin ;

Bryce, Richard ;

Carey, Lisa A. .

JAMA ONCOLOGY, 2016, 2 (12) :1557-1564

[8] Impact of tucatinib on progression free survival in patients with HER2+metastatic breast cancer and stable or active brain metastases [J].

Bachelot, T. ;

Lin, N. U. ;

Murthy, R. K. ;

Hurvitz, S. A. ;

Borges, V. ;

Oliveira, M. ;

Oakman, C. ;

Khan, S. ;

Lynch, C. ;

Westbrook, K. ;

Doyle, C. ;

Reinisch, M. ;

Colleoni, M. A. ;

Slamon, D. ;

Hortobagyi, G. N. ;

Winer, E. P. ;

McGoldrick, S. ;

An, X. ;

Loibl, S. .

ANNALS OF ONCOLOGY, 2020, 31 :S359-S360

[9] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].

Bachelot, Thomas ;

Romieu, Gilles ;

Campone, Mario ;

Dieras, Veronique ;

Cropet, Claire ;

Dalenc, Florence ;

Jimenez, Marta ;

Le Rhun, Emilie ;

Pierga, Jean-Yves ;

Goncalves, Anthony ;

Leheurteur, Marianne ;

Domont, Julien ;

Gutierrez, Maya ;

Cure, Herve ;

Ferrero, Jean-Marc ;

Labbe-Devilliers, Catherine .

LANCET ONCOLOGY, 2013, 14 (01) :64-71

[10] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

← 1 2 3 4 5 6 7 8 9 10 →